Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Predictive Biosciences Announces Next-Generation Sequencing Assay for p53

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Predictive Biosciences announced it has developed a new next-generation sequencing (NGS) assay for the TP53 gene (encoding the p53 protein) that will enhance the clinical performance of its bladder cancer assay.

The new CertNDx(TM) Bladder Cancer Assay incorporating TP53 is expected to be commercially available in early 2013.

Predictive's next-generation sequencing assay for TP53 can detect 133 different mutations previously identified in bladder cancers. A research study conducted on 200 control samples and 36 cancers, incorporating TP53 sequence analysis into the existing assay, demonstrated an improvement over the previously published test by increasing sensitivity across bladder cancer pathways while retaining very high specificity and high Positive Predictive Value (PPV). The performance of this assay will also be validated in a large, prospective clinical trial to be completed in the first quarter of 2013.

The CertNDx test now fully incorporates the different pathways of bladder cancer. One pathway consists of primarily low-grade cancers, which are characterized predominantly by mutations in FGFR3. A second pathway consists of mostly high-grade cancers or carcinoma in situ lesions, which typically have mutations in TP53. These TP53 mutant tumors are more likely to be associated with a more aggressive clinical course and a very high likelihood of progression to a life threatening disease.

"By combining p53 with our current FGFR3 assay, we can provide excellent detection for both pathways, covering all stages and grades of bladder cancer," said Anthony P. Shuber, Chief Technology Officer. "In addition to incorporating p53 into the existing CertNDx assay, we are developing a version of the assay which integrates all of the CertNDx biomarkers in a format which can be run on any NGS platform, making it ready for in vitro diagnostic kit development."

Marc Schneebaum, Chief Executive Officer, added, "We are very excited that p53 further optimizes the performance of our NGS-based CertNDx test. This evolution of our test provides another compelling example of how Predictive's unique diagnostic approach and portfolio of clinically validated biomarkers leverages the ongoing innovation in NGS platform technology to add true clinical value."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Predictive Biosciences Appoints Dr. Angelo De Marzo to Leadership Team
Angelo M. De Marzo, M.D., Ph.D., arrives with an extensive background in prostate cancer research and urological pathology practice. Dr. De Marzo has been a faculty member at The Johns Hopkins University (JHU) School of Medicine since 1998.
Friday, January 06, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
DNA Damage Seen in Patients Undergoing CT Scanning
Along with the burgeoning use of advanced medical imaging tests over the past decade have come rising public health concerns about possible links between low-dose radiation and cancer.
The Light of Fireflies for Medical Diagnostics
EPFL scientists have exploited the light of fireflies in a new method that detects biological molecules without the need for complex devices and high costs.
Vital Protein in Healthy Fertilization Process Identified
Researchers at the National Institutes of Health have discovered a protein that plays a vital role in healthy egg-sperm union in mice.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!